LipoKnoxa™ Human APOA5 shRNA Lentiviral Particle (Silencing)

Sub Cat. No.	TargetSeq	Region	Inquiry
V0126XX499-1	CCATGCATGTGGGTGATTATC	3' UTR	Inquiry
V0126XX499-2	AGGACACCTACCTGCAGATAG	CDS	Inquiry
V0126XX499-3	CAATCTGGATGCATTACATTC	3' UTR	Inquiry
V0126XX499-4	Other		Inquiry

Product Overview

Description: LipoKnoxa™ Human APOA5 shRNA Lentiviral Particle (Silencing) targets APOA5, a major regulator of plasma triglyceride levels. Our platform offers both U6 and miR30-based shRNA for stable modulation of lipid clearance pathways. Every viral preparation is backed by comprehensive QC documentation, confirming functional titer, sterility, and sequence integrity for reliable research in hepatocyte models.

Production Cell Line: HEK293T

Promoter: U6; CMV; EF1α; CAG; UBC

Product Availability: Produced Upon Order

Specification

Titer Test: qPCR

Insert Verification: Comprehensive sequencing and PCR analyses were performed to verify the accurate genomic sequence of all viral preparations.

Sterility Test: Confirmed sterile via rigorous microbial analysis; free of bacterial and fungal contamination.

Mycoplasma Test: Rigorous quality control testing has confirmed the absence of mycoplasma contamination in this viral preparation.

Other QC: Customized supplementary testing and in vitro/in vivo assessments are available to verify post-silencing gene expression and biological functionality, ensuring the viral preparations meet the specific potency requirements of your gene interference project.

Storage: Store at -80°C for long-term preservation. Immediate transfer upon delivery is required to prevent loss of viral activity.

Stability: Shelf life: 6–12 months at -80°C (extended stability up to 2 years). Post-thaw: Stable at 4°C for 2–3 weeks without significant degradation of functional titers.

Shipping Condition: Products are delivered on dry ice to maintain the cold chain. Upon arrival, please ensure the presence of dry ice and transfer the vials immediately to -80°C storage.

Handling Notes: Avoid repeated freeze-thaw cycles. Aliquot into low-protein-binding tubes immediately after receipt to maintain optimal activity. For safety and contamination control, all viral handling must be performed inside a biosafety cabinet.

Intended Use: This product is intended for research use only and is not for use in diagnosis or therapeutic applications.

Product Disclaimer: We ensure product integrity through rigorous QC, but we do not guarantee results in specific research contexts. Proper storage, handling, and total compliance with biosafety laws and safety protocols remain the sole responsibility of the user.

Target Profile

Gene Name: APOA5

Full Name: Apolipoprotein A5

Gene Symbol: RAP3; APOAV

Gene ID: 116519

RefSeq ID-1: NP_001160070.1

RefSeq ID-2: NM_001166598.2

Summary: APOA5 encodes an apolipoprotein critical for plasma triglyceride regulation, a key factor in cardiovascular disease risk. It is part of high-density lipoproteins, and mutations can cause hypertriglyceridemia or hyperlipoproteinemia type 5. Dysregulated APOA5-mediated lipid metabolism can influence obesity development.

LipoKnoxa™ Human APOA5 shRNA Lentiviral Particle (Silencing)

Product Overview

Specification

Target Profile

Related Products